The current financial score of Immunocore Holdings PLC is 7.45. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 115.93M, representing a year-over-year increase of 18.34%, while its net profit experienced a year-over-year increase of 92.16%.
The current valuation score of Immunocore Holdings PLC is 9.61. Its current P/E ratio is -58.17, which is -52.55% below the recent high of -27.60 and -57.82% above the recent low of -91.80.
The current earnings forecast score of Immunocore Holdings PLC is 7.87. The average price target is 64.25, with a high of 91.00 and a low of 34.00.
The current price momentum score of Immunocore Holdings PLC is 4.63. Currently, the stock price is trading between the resistance level at 36.26 and the support level at 29.44, making it suitable for range-bound swing trading.
The current institutional shareholding score of Immunocore Holdings PLC is 10.00. The latest institutional shareholding proportion is 97.50%, representing a quarter-over-quarter decrease of 4.15%. The largest institutional shareholder is PRIMECAP Management, holding a total of 3.64M shares, representing 0.07% of shares outstanding, with 3.96% increase in holdings.
The current risk assessment score of Immunocore Holdings PLC is 7.55. The company's beta value is 0.75. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.